CIRIUS THERAPEUTICS
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH. Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.
CIRIUS THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Device Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Kalamazoo, Michigan, United States
Country:
United States
Website Url:
http://www.ciriustx.com
Total Employee:
11+
Status:
Active
Contact:
(269)343-6732
Total Funding:
49 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics WordPress Google Universal Analytics Mobile Non Scaleable Content Sitelinks Search Box Euro Organization Schema
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Cirius Therapeutics
Adams Street Partners
Adams Street Partners investment in Series A - Cirius Therapeutics
Novo Holdings
Novo Holdings investment in Series A - Cirius Therapeutics
Hopen Life Science Ventures
Hopen Life Science Ventures investment in Series A - Cirius Therapeutics
Novo Holdings
Novo Holdings investment in Series A - Cirius Therapeutics
Renaissance Venture Capital
Renaissance Venture Capital investment in Series A - Cirius Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Cirius Therapeutics
Adams Street Partners
Adams Street Partners investment in Series A - Cirius Therapeutics
Official Site Inspections
http://www.ciriustx.com Semrush global rank: 8.14 M Semrush visits lastest month: 359
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 76.223.105.230
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Cirius Therapeutics"
Cirius
Cirius Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for diseases caused by insulin resistance including Type 2 Diabetes, the metabolic …See details»
Leadership | Cirius - ciriustx.com
Insulin resistance, a root cause of type 2 diabetes, is considered a key factor in the initiation and perpetuation of NASH. NASH patients with diabetes have been shown to have more advanced fibrosis, are prone to a more rapid progression …See details»
Our Story - Cirius Group
In the 1980s when our founder was working in healthcare. He saw first hand how the manually intensive billing process created stress for employees and cash flow issues for the …See details»
Revenue Cycle Solutions - Cirius Group
We help our partners determine the best fit for their organization based on payer mix. Cirius is so effective that close to 50% of the billing staff has been reallocated and production quality has …See details»
Cirius Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Cirius Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Cirius Group, Inc. Results Driven Revenue Cycle Solutions
Solutions . The Cirius Group's flexible, scalable, and customizable solutions transform healthcare organizations into the most efficient financial powerhouses in nation.See details»
Cirius Therapeutics - Overview, News & Similar companies
View Cirius Therapeutics (www.ciriustx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Working At Cirius Therapeutics: Company Overview and Culture
Ciriustx.com. Organization Type. Private. CEO. Robert F Baltera. Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin …See details»
Board of Directors | Cirius - ciriustx.com
Board of Directors – Michael Jandernoa 04/03/2016 / by eallison. David Van Andel 04/03/2016 / by eallisonSee details»
Cirius Therapeutics, Inc. in San Diego, CA - (858) 333-6274 - Profile
Cirius Therapeutics, Inc. is in the Physical Therapist business. View competitors, revenue, employees, website and phone number.See details»
Insulin sensitizers in 2023: lessons learned and new avenues for ...
Sep 27, 2023 Jerry R. Colca a CSO, Cirius Therapeutics Inc, Kalamazoo, MI, USA Correspondence [email protected] View further author information, Steven P. Tanis b SP ...See details»
Resources Page - Cirius Group
Our story begins in the 1980's when our founder was working in healthcare. He saw firsthand how the manually intensive billing process created stress for employees and cash flow issues for …See details»
Cirius Therapeutics Company Profile 2024: Valuation, Funding ...
Cirius Therapeutics General Information Description. Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's sensitizer drug is …See details»
Cirius Therapeutics Announces Presentation of Interim Data from …
Apr 12, 2019 SAN DIEGO and KALAMAZOO, Mich., April 12, 2019 /PRNewswire/ -- Cirius Therapeutics announced today that positive results from an interim analysis of exploratory …See details»
Publications | Cirius - ciriustx.com
Colca JR, McDonald WG, Adams WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.Expert Opin Investig Drugs. 2018 Jul;27(7):631-636. …See details»
NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular ...
Jan 23, 2020 Jerry Colca Cirius Therapeutics, Kalamazoo, MI, USA;Cirius Therapeutics, San Diago, CA, USA Correspondence [email protected] View further author information Pages …See details»
Cirius Therapeutics Announces Results from Phase 2b NASH Study ...
Nov 8, 2019 Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker …See details»
News - Cirius
Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics’ MSDC-0602K Showed Improved Insulin HandlingSee details»
Cirius Therapeutics to Present Preclinical Data for Lead Drug …
Mar 27, 2019 SAN DIEGO and KALAMAZOO, Mich., March 27, 2019 /PRNewswire/ -- Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and …See details»